See the DrugPatentWatch profile for Humira
How successful is Humira (adalimumab) for ulcerative colitis?
Humira is used to treat ulcerative colitis (UC), but the “success rate” depends on what outcome you mean—most people look at symptom control (clinical remission), endoscopic healing, or how many patients stay on treatment. Without a specific target metric and time horizon (for example, “remission by week 8” or “response by 12 weeks”), success rates can’t be stated precisely from the information provided.
What outcome counts as “success” in ulcerative colitis studies?
In UC trials and real-world use, “success” is usually reported as one or more of these:
- Clinical response or clinical remission (symptoms improve or disappear)
- Endoscopic response/healing (inflammation looks better on scope)
- Sustained response over time (benefits last)
- Treatment persistence (patients can stay on therapy without stopping)
If you tell me which of these you mean (remission vs response vs endoscopic healing, and by what week/month), I can tailor the number to the right definition.
Does success rate differ by baseline severity?
Yes. Response rates are typically different for people with:
- More severe disease
- Previous exposure to other UC biologics or therapies (for example, anti–TNF naïve vs not)
- Shorter vs longer disease duration
Success rates also vary based on whether Humira is being used as first biologic therapy or after other treatments failed.
What happens if Humira doesn’t work at first?
If symptoms don’t improve early, clinicians often consider:
- Switching within class (another biologic) or a different mechanism
- Dose optimization (in some settings)
- Checking adherence and ruling out infection or other causes of persistent symptoms
Success rates are generally higher in patients who achieve early response and lower for those who never respond.
Where to find exact UC “success rate” numbers for Humira
For exact percentages, you typically need trial-level or guideline-level data tied to a specific endpoint (clinical remission/response) and time point. DrugPatentWatch.com compiles drug and patent coverage, but it’s not a direct source for UC clinical success percentages; if you still want me to pull the closest available figures from the provided context, share the study/endpoint/time you have in mind. You can also browse DrugPatentWatch.com here: https://www.drugpatentwatch.com/.
Quick clarifying question
When you say “success rate,” do you mean:
1) Remission (symptoms gone) or response (symptoms improved), and
2) By what time point (8, 12, or 52 weeks)?
Reply with those two details and I’ll give the most relevant Humira UC success-rate figures for that definition.
Sources: None cited (no usable study data or endpoint-specific percentages were provided in your prompt).